MICROBIOTIX, INC
Development of well tolerated novel Inhibitors of drug resistant CMV
Development of well tolerated novel Inhibitors of drug resistant CMV is a funding opportunity from MICROBIOTIX, INC, up to 298582, closing July 31, 2027.
Jul 31, 2027
(365d left)Overview
CMV occurs as a benign infection in most humans, with an estimated 60-90% of the population infected during their lives. However, in immunosuppressed patients, particularly in recipients of solid organ or bone marrow transplants, allogenic CMV infection is a major cause of morbidity and mortality. Approximately 30,000…